Amgen, Janssen Biotech collaborate on multiple myeloma treatment

Amgen will partner with Janssen Biotech to assess the drug combination made up of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen, over the course of multiple clinical trials for the treatment of patients who have multiple myeloma.
"Given the relapsing nature of multiple myeloma, several options are needed to attack the disease differently and keep patients in remission as long as possible," Amgen Executive Vice President of Research and Development Dr. Sean Harper said. "We are excited to collaborate with Janssen to evaluate the potential of combining KYPROLIS, a powerful proteasome inhibitor, with DARZALEX, the first human anti-CD38 monoclonal antibodyfor the treatment of multiple myeloma in the relapsed setting."
The first event that has been initiated by the partnership is a Phase 3 trial that will evaluate the KYPROLIS and DARZALEX combination along with dexamethasone in comparison to KYPROLIS and dexamethasone as standalone treatments in multiple myeloma patients who have previously undergone one, two or three treatments of prior therapy.
The two companies are collaborating to combine their drugs because they are complementary of each other and each has shown a high level of activity in multiple myeloma.